Another deal went south for Thoratec Corp. (NSDQ:THOR), this time over concerns with its International Technidyne Corp. division’s regulatory and quality systems and the failure of a key product to win a green light from the Food & Drug Administration.
The Pleasanton, Calif.-based cardiac assist device maker scuttled its deal with Danaher Corp. (NYSE:DHR) for a $110 million buyout of ITC, saying the parties couldn’t agree on "the status of certain aspects of ITC’s quality system and regulatory filings," according to a press release.